HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer
Cancer Medicine · 2025-12 · 14 (23)
DOI: 10.1002/cam4.71415 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 08.12.2025. Verfasst von Seohyuk Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other candidates under ongoing investigation.
Methods
In this report, we provide a narrative review of existing data underlying the current understanding of HER2‐targeted ADC toxicities in breast cancer, highlighting both common and serious adverse events.
Results
When used as an adjuvant or neoadjuvant, first‐ or second‐line agent, alone or in combination with another agent, trastuzumab emtansine has been commonly associated with epistaxis, fatigue, headache, nausea, and pyrexia across several clinical trials. Comparatively, trastuzumab deruxtecan has been commonly associated with alopecia, cytopenias, decreased appetite, fatigue, and gastrointestinal adverse effects.
Conclusion
Despite the demonstrated clinical benefits in breast cancer, diverse systemic and organ‐specific adverse events, including dose‐limiting toxicities, have been reported even at suboptimal therapeutic doses and pose significant barriers to pursuing dose escalations for maximizing therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut, USA.
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
- Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Maryam B Lustberg
Zitieren
APA
Lee, S., Kahn, A. M., Rozenblit, M., George, M. A., Naranjo Ortiz, C., & Lustberg, M. B. (2025). HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine, 14(23). https://doi.org/10.1002/cam4.71415
Vancouver
Lee S, Kahn AM, Rozenblit M, George MA, Naranjo Ortiz C, Lustberg MB. HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine. 2025;14(23). doi:10.1002/cam4.71415
BibTeX
@article{Lee2025,
author = {Lee, Seohyuk and Kahn, Adriana M and Rozenblit, Mariya and George, Mridula A and Naranjo Ortiz, Cristina and Lustberg, Maryam B},
title = {HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {23},
doi = {10.1002/cam4.71415}
}
EUVIMED